newsfilter
← Latest News
GlobeNewswire·

VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update

OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023 Completed patient enrollment in the 409 patient OV